ERBB2 and breast carcinoma: Similarly, absolute HER2 quantification in an homogeneous group of HER2-positive breast cancer (IHC 3+) using triple quadrupole MS was predictive of a better response to trastuzumab in both adjuvant and metastatic settings [136].